(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three most active and biggest winners today are Hycroft Mining Holding Corporation, Marathon, and Canopy Growth.

Rank Financial Asset Price Change Updated (EST)
1 Hycroft Mining Holding Corporation (HYMCW) 0.23 22.22% 2022-07-18 13:15:07
2 Marathon (MARA) 9.75 21.27% 2022-07-18 14:59:49
3 Canopy Growth (CGC) 2.59 15.4% 2022-07-18 14:59:21
4 Riot Blockchain (RIOT) 6.23 11.85% 2022-07-18 14:50:11
5 First Trust Developed Markets ex-US Small Cap AlphaDEX Fund (FDTS) 37.02 10.71% 2022-07-17 19:47:12
6 Happiness Biotech Group Limited (HAPP) 0.23 8.96% 2022-07-18 09:10:06
7 Coinbase (COIN) 58.52 8.79% 2022-07-18 14:54:22
8 Hall of Fame Resort & Entertainment Company (HOFV) 0.70 8.6% 2022-07-18 11:09:07
9 U.S. Gold Corp (USAU) 3.92 8.59% 2022-07-18 14:38:30
10 Esports Entertainment Group (GMBLW) 0.07 8.02% 2022-07-18 05:09:07

The three most active and biggest losers today are iFresh, Greenrose Acquisition Corp., and Frequency Therapeutics.

Rank Financial Asset Price Change Updated (EST)
1 iFresh (IFMK) 0.02 -33.33% 2022-07-18 14:32:45
2 Greenrose Acquisition Corp. (GNRS) 2.68 -16.25% 2022-07-18 05:15:05
3 Frequency Therapeutics (FREQ) 2.24 -12.16% 2022-07-17 23:13:05
4 Greenrose Acquisition Corp. (GNRSW) 0.13 -10.34% 2022-07-18 05:23:13
5 Pacific Biosciences of California (PACB) 3.93 -7.31% 2022-07-18 14:58:38
6 ImmunoGen (IMGN) 5.01 -6.97% 2022-07-18 14:59:00
7 Celsius Holdings (CELH) 75.31 -6.88% 2022-07-18 14:48:19
8 Nano Dimension (NNDM) 3.12 -6.74% 2022-07-18 14:49:46
9 Hycroft Mining Holding Corporation (HYMCZ) 0.07 -6.68% 2022-07-18 13:17:07
10 Arcturus Therapeutics (ARCT) 15.73 -6.06% 2022-07-18 14:47:49

Most Active Winners today

1. Hycroft Mining Holding Corporation (HYMCW) – 22.22%

Hycroft Mining Holding Corporation and its subsidiaries operate as an American gold-silver producer. It holds interest in Hycroft Mine, which covers an area of 70,671 acres in Nevada. The company’s Hycroft mine was estimated to have proven and probable mineral resources of approximately 11.9 million ounces gold and 478.5 millions ounces silver as of December 31, 2020. Hycroft Mining Holding Corporation used to be known as Mudrick Capital Acquisition Corporation. It was founded in 2017 in Denver, Colorado.

NASDAQ ended the session with Hycroft Mining Holding Corporation jumping 22.22% to $0.23 on Monday while NASDAQ fell 0.81% to $11,360.05.

Hycroft Mining Holding Corporation’s last close was $0.20, 17.53% under its 52-week high of $0.24.

Hycroft Mining Holding Corporation’s Revenue

Year-on-year quarterly revenue growth declined by 51.8%, now sitting on 100.86M for the twelve trailing months.

Hycroft Mining Holding Corporation’s Stock Yearly Top and Bottom Value

Hycroft Mining Holding Corporation’s stock is valued at $0.23 at 17:32 EST, under its 52-week high of $0.24 and way higher than its 52-week low of $0.19.

More news about Hycroft Mining Holding Corporation.

2. Marathon (MARA) – 21.27%

Marathon Patent Group, Inc. is a company which mines cryptocurrency. The company owns cryptocurrency mining equipment and a Quebec data center that can mine digital assets. The former name of the company was American Strategic Minerals Corporation. In February 2013, Marathon Patent Group, Inc. took over its operations. Marathon Patent Group, Inc. was established in 2010. It is located in Las Vegas, Nevada.

NASDAQ ended the session with Marathon rising 21.27% to $9.75 on Monday, after three sequential sessions in a row of gains. NASDAQ slid 0.81% to $11,360.05, after two successive sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Volume

Today’s last reported volume for Marathon is 42947800 which is 230.91% above its average volume of 12978500.

Marathon’s last close was $8.04, 90.37% under its 52-week high of $83.45.

Marathon’s Sales

Marathon’s sales growth is 286.1% for the current quarter and 236.5% for the next. The company’s growth estimates for the current quarter and the next is 137.6% and 377.3%, respectively.

Marathon’s Revenue

Year-on-year quarterly revenue growth grew by 2180.3%, now sitting on 150.46M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Marathon’s stock is considered to be oversold (<=20).

Marathon’s Stock Yearly Top and Bottom Value

Marathon’s stock is valued at $9.75 at 17:32 EST, way under its 52-week high of $83.45 and way above its 52-week low of $5.20.

Marathon’s Moving Average

Marathon’s value is way above its 50-day moving average of $8.83 and way under its 200-day moving average of $28.19.

More news about Marathon.

3. Canopy Growth (CGC) – 15.4%

NASDAQ ended the session with Canopy Growth jumping 15.4% to $2.59 on Monday, after two sequential sessions in a row of losses. NASDAQ slid 0.81% to $11,360.05, after two sequential sessions in a row of gains, on what was a somewhat down trend trading session today.

Volume

Today’s last reported volume for Canopy Growth is 19840800 which is 179.45% above its average volume of 7099730.

Canopy Growth’s last close was $2.24, 96.04% under its 52-week high of $56.50.

Canopy Growth’s Revenue

Year-on-year quarterly revenue growth grew by 23.4%, now sitting on 572.44M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Canopy Growth’s stock is considered to be overbought (>=80).

Canopy Growth’s Stock Yearly Top and Bottom Value

Canopy Growth’s stock is valued at $2.59 at 17:32 EST, way under its 52-week low of $9.54.

Canopy Growth’s Moving Average

Canopy Growth’s value is way below its 50-day moving average of $12.63 and way below its 200-day moving average of $20.75.

More news about Canopy Growth.

4. Riot Blockchain (RIOT) – 11.85%

NASDAQ ended the session with Riot Blockchain rising 11.85% to $6.23 on Monday while NASDAQ dropped 0.81% to $11,360.05.

Volume

Today’s last reported volume for Riot Blockchain is 37933100 which is 203.36% above its average volume of 12504100.

Riot Blockchain’s last close was $5.57, 87.96% under its 52-week high of $46.28.

Riot Blockchain’s Sales

Riot Blockchain’s sales growth is 1759.8% for the ongoing quarter and 411.3% for the next. The company’s growth estimates for the current quarter and the next is 212.5% and 444.4%, respectively.

Riot Blockchain’s Revenue

Year-on-year quarterly revenue growth grew by 2532.3%, now sitting on 127.64M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Riot Blockchain’s stock is considered to be oversold (<=20).

Riot Blockchain’s Stock Yearly Top and Bottom Value

Riot Blockchain’s stock is valued at $6.23 at 17:32 EST, under its 52-week low of $6.25.

Riot Blockchain’s Moving Average

Riot Blockchain’s value is way below its 50-day moving average of $15.16 and way under its 200-day moving average of $24.25.

More news about Riot Blockchain.

5. First Trust Developed Markets ex-US Small Cap AlphaDEX Fund (FDTS) – 10.71%

NASDAQ ended the session with First Trust Developed Markets ex-US Small Cap AlphaDEX Fund rising 10.71% to $37.02 on Monday, following the last session’s upward trend. NASDAQ slid 0.81% to $11,360.05, after two sequential sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Volume

Today’s last reported volume for First Trust Developed Markets ex-US Small Cap AlphaDEX Fund is 24 which is 98.87% below its average volume of 2127.

More news about First Trust Developed Markets ex-US Small Cap AlphaDEX Fund.

6. Happiness Biotech Group Limited (HAPP) – 8.96%

Happiness Biotech Group Limited is engaged in research, development and manufacture of nutraceutical products and dietary supplements in China as well as internationally. Products include lucidumspore powder and cordyceps Mycelia. The company also sells ganodermalucidum products such as cleansing milk, essence oil, shampoo, conditioner, and shower gel under its Cai ZhiNing brand. It also has nourishing cream products that contain edible fungi. The company also offers COVID-19 antibody testing kits, disinfectants and non-medical facial masks. The company sells products via distributors and large-scale chain pharmacies. Happiness Biotech Group Limited, based in Nanping in the People’s Republic of China was established in 2004.

NASDAQ ended the session with Happiness Biotech Group Limited jumping 8.96% to $0.23 on Monday, after two sequential sessions in a row of losses. NASDAQ slid 0.81% to $11,360.05, after two successive sessions in a row of gains, on what was a somewhat bearish trend trading session today.

Volume

Today’s last reported volume for Happiness Biotech Group Limited is 110818 which is 93.47% below its average volume of 1698450.

Happiness Biotech Group Limited’s last close was $0.22, 85.97% below its 52-week high of $1.54.

Happiness Biotech Group Limited’s Revenue

Year-on-year quarterly revenue growth grew by 114.3%, now sitting on 96.49M for the twelve trailing months.

Happiness Biotech Group Limited’s Stock Yearly Top and Bottom Value

Happiness Biotech Group Limited’s stock is valued at $0.23 at 17:32 EST, way under its 52-week high of $1.54 and way above its 52-week low of $0.13.

Happiness Biotech Group Limited’s Moving Average

Happiness Biotech Group Limited’s value is way above its 50-day moving average of $0.20 and way under its 200-day moving average of $0.47.

More news about Happiness Biotech Group Limited.

7. Coinbase (COIN) – 8.79%

NASDAQ ended the session with Coinbase jumping 8.79% to $58.52 on Monday while NASDAQ slid 0.81% to $11,360.05.

Volume

Today’s last reported volume for Coinbase is 20458200 which is 45.35% above its average volume of 14074700.

Coinbase’s last close was $53.79, 85.42% below its 52-week high of $368.90.

News about Coinbase today

  • Stocks making the biggest moves in the premarket: Goldman Sachs, synchrony financial, coinbase and more. According to today’s article on CNBC, "Coinbase (COIN) – Coinbase rallied 6.5% in premarket action, with the cryptocurrency exchange operator’s stock one of several crypto-related stocks rising after the value of bitcoin and ether surged in overnight trading."

The company’s growth estimates for the current quarter and the next is a negative 97.7% and a negative 101.2%, respectively.

Coinbase’s Revenue

Year-on-year quarterly revenue growth grew by 327.1%, now sitting on 7.84B for the twelve trailing months.

Coinbase’s Stock Yearly Top and Bottom Value

Coinbase’s stock is valued at $58.52 at 17:32 EST, way below its 52-week high of $368.90 and way above its 52-week low of $40.83.

Coinbase’s Moving Average

Coinbase’s value is way below its 50-day moving average of $107.90 and way under its 200-day moving average of $210.61.

More news about Coinbase.

8. Hall of Fame Resort & Entertainment Company (HOFV) – 8.6%

Hall of Fame Resort & Entertainment Company is a resort/entertainment company that does business under the Pro Football Hall of Fame. The company is the owner of the Pro Football Hall of Fame, a premier media, sports and entertainment enterprise in Canton. Canton is the headquarters of this company, which was established in 2015.

NASDAQ ended the session with Hall of Fame Resort & Entertainment Company rising 8.6% to $0.70 on Monday while NASDAQ fell 0.81% to $11,360.05.

Volume

Today’s last reported volume for Hall of Fame Resort & Entertainment Company is 313839 which is 67.84% below its average volume of 976039.

Hall of Fame Resort & Entertainment Company’s last close was $0.64, 81.84% under its 52-week high of $3.54.

Hall of Fame Resort & Entertainment Company’s Revenue

Year-on-year quarterly revenue growth grew by 10%, now sitting on 10.96M for the twelve trailing months.

Hall of Fame Resort & Entertainment Company’s Stock Yearly Top and Bottom Value

Hall of Fame Resort & Entertainment Company’s stock is valued at $0.70 at 17:32 EST, way under its 52-week high of $3.54 and way higher than its 52-week low of $0.52.

Hall of Fame Resort & Entertainment Company’s Moving Average

Hall of Fame Resort & Entertainment Company’s value is above its 50-day moving average of $0.64 and way under its 200-day moving average of $1.34.

More news about Hall of Fame Resort & Entertainment Company.

9. U.S. Gold Corp (USAU) – 8.59%

NASDAQ ended the session with U.S. Gold Corp rising 8.59% to $3.92 on Monday while NASDAQ slid 0.81% to $11,360.05.

Volume

Today’s last reported volume for U.S. Gold Corp is 32623 which is 17.27% below its average volume of 39434.

U.S. Gold Corp’s last close was $3.57, 79.48% below its 52-week high of $17.40.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

U.S. Gold Corp’s stock is considered to be overbought (>=80).

U.S. Gold Corp’s Stock Yearly Top and Bottom Value

U.S. Gold Corp’s stock is valued at $3.92 at 17:32 EST, way below its 52-week low of $8.50.

U.S. Gold Corp’s Moving Average

U.S. Gold Corp’s worth is way under its 50-day moving average of $10.13 and way under its 200-day moving average of $10.50.

More news about U.S. Gold Corp.

10. Esports Entertainment Group (GMBLW) – 8.02%

NASDAQ ended the session with Esports Entertainment Group jumping 8.02% to $0.07 on Monday while NASDAQ dropped 0.81% to $11,360.05.

Esports Entertainment Group’s last close was $0.07, 34% below its 52-week high of $0.10.

Esports Entertainment Group’s Stock Yearly Top and Bottom Value

Esports Entertainment Group’s stock is valued at $0.07 at 17:32 EST, way below its 52-week high of $0.10 and way above its 52-week low of $0.06.

More news about Esports Entertainment Group.

Most Active Losers Today

1. iFresh (IFMK) – -33.33%

Through its subsidiaries, iFresh Inc. operates a network grocery store chains in the northern-eastern United States. The company operates in two segments: Wholesale and Retail. It offers vegetables, seafood and meats as well as snacks and seasonings. The company’s brands include Feiyan and Green Acre as well as Redolent, Redolent and Golden Smell. It also sells products in wholesale shops, supermarkets and restaurants. It had nine supermarkets, two wholesale shops and one in-house business. It sells its products online and has a delivery network throughout suburban areas. Founded in 1995, iFresh Inc. is headquartered on Long Island City in New York.

NASDAQ ended the session with iFresh sliding 33.33% to $0.02 on Monday while NASDAQ slid 0.81% to $11,360.05.

Volume

Today’s last reported volume for iFresh is 595 which is 40.2% below its average volume of 995.

iFresh’s last close was $0.03, 98.21% below its 52-week high of $1.68.

iFresh’s Revenue

Year-on-year quarterly revenue growth grew by 22.7%, now sitting on 94.26M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

iFresh’s stock is considered to be oversold (<=20).

iFresh’s Stock Yearly Top and Bottom Value

iFresh’s stock is valued at $0.02 at 17:32 EST, way under its 52-week high of $1.68 and way higher than its 52-week low of $0.00.

iFresh’s Moving Average

iFresh’s worth is way above its 50-day moving average of $0.01 and way under its 200-day moving average of $0.28.

More news about iFresh.

2. Greenrose Acquisition Corp. (GNRS) – -16.25%

Greenrose Acquisition Corp. doesn’t have any significant operations. The company plans to merge, exchange shares, acquire assets, stock buy, recapitalization and reorganize with other businesses. It was founded in Amityville in New York in 2019.

NASDAQ ended the session with Greenrose Acquisition Corp. sliding 16.25% to $2.68 on Monday, following the last session’s downward trend. NASDAQ dropped 0.81% to $11,360.05, after two successive sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Volume

Today’s last reported volume for Greenrose Acquisition Corp. is 932 which is 67.28% below its average volume of 2849.

Greenrose Acquisition Corp.’s last close was $2.68, 74.76% below its 52-week high of $10.62.

Greenrose Acquisition Corp.’s Revenue

Year-on-year quarterly revenue growth grew by 14.5%, now sitting on 24.16M for the twelve trailing months.

Greenrose Acquisition Corp.’s Stock Yearly Top and Bottom Value

Greenrose Acquisition Corp.’s stock is valued at $2.68 at 17:32 EST, way under its 52-week high of $10.62 and way above its 52-week low of $1.05.

Greenrose Acquisition Corp.’s Moving Average

Greenrose Acquisition Corp.’s value is way above its 50-day moving average of $2.13 and way under its 200-day moving average of $4.74.

More news about Greenrose Acquisition Corp..

3. Frequency Therapeutics (FREQ) – -12.16%

Frequency Therapeutics Inc. is a biotech company in clinical stage. It focuses on harnessing the body’s natural biology to reverse or repair damage from a variety of degenerative conditions. The company’s Progenitor Cell Activation method uses small molecules to activate the progenitor cells in the body and create functional tissue. FX-322 is the company’s leading product candidate and is currently in phase IIa clinical trials to address the root cause of sensorineural loss. The company is developing medications for patients with a variety of degenerative conditions including multiple sclerosis and diseases of muscle, gastrointestinal tract and skin. Frequency Therapeutics Inc. is a licensed and collaborative partner with Astellas Pharma Inc. to develop and commercialize FX-322. There are also collaboration and licensing agreements between Massachusetts Eye and Ear and Mass General Brigham and the Massachusetts Institute of Technology and The Scripps Research Institute. It was founded in Lexington, Massachusetts in 2014.

NASDAQ ended the session with Frequency Therapeutics dropping 12.16% to $2.24 on Monday while NASDAQ slid 0.81% to $11,360.05.

Volume

Today’s last reported volume for Frequency Therapeutics is 754507 which is 7.96% above its average volume of 698813.

Frequency Therapeutics’s last close was $2.24, 73.95% below its 52-week high of $8.60.

The company’s growth estimates for the present quarter is a negative 28.8% and positive 17.8% for the next.

Frequency Therapeutics’s Stock Yearly Top and Bottom Value

Frequency Therapeutics’s stock is valued at $2.24 at 17:32 EST, way below its 52-week high of $8.60 and way above its 52-week low of $1.00.

Frequency Therapeutics’s Moving Average

Frequency Therapeutics’s value is way higher than its 50-day moving average of $1.38 and way under its 200-day moving average of $3.72.

More news about Frequency Therapeutics.

4. Greenrose Acquisition Corp. (GNRSW) – -10.34%

NASDAQ ended the session with Greenrose Acquisition Corp. dropping 10.34% to $0.13 on Monday while NASDAQ slid 0.81% to $11,360.05.

Greenrose Acquisition Corp.’s last close was $0.13, 13.33% under its 52-week high of $0.15.

Greenrose Acquisition Corp.’s Stock Yearly Top and Bottom Value

Greenrose Acquisition Corp.’s stock is valued at $0.13 at 17:32 EST, way under its 52-week high of $0.15 and way above its 52-week low of $0.11.

More news about Greenrose Acquisition Corp..

5. Pacific Biosciences of California (PACB) – -7.31%

Pacific Biosciences of California, Inc. develops, manufactures, and markets sequencing systems for complex genetic problems. The single-molecule real time (SMRT), sequencing technology allows for single-molecule detection of biological processes. The company offers a range of consumable products including SMRT cell technology and various reagent kit kits for specific workflows such as template preparation in order to transform DNA into SMRTbell double stranded DNA libraries formats. This includes molecular biology reagents such as ligase buffers exonucleases, buffers, and ligase. It also offers binding kits such as the modified DNA polymerase, which is used to bind SMRTbell library formats to the polymerase, in preparation to sequencing. Sequencing kits include reagents that are required to perform on-instrument real-time sequencing including the phospholinked nucleotides. It serves commercial labs, genome centers, research institutes, genomics service providers, pharmaceutical companies, and agricultural businesses. The company markets its products via a direct sales force throughout North America and Europe as well as distribution partners across Asia, Europe and the Middle East. Asuragen and Pacific Biosciences have partnered to create assays that can be used for carrier screening, and many other purposes. They use SMRT sequencing technology. The original name of the company was Nanofluidics, Inc., but it changed its name in 2005 to Pacific Biosciences of California, Inc. Pacific Biosciences of California, Inc., was established in 2000. It is located in Menlo Park, California.

NASDAQ ended the session with Pacific Biosciences of California sliding 7.31% to $3.93 on Monday, after two sequential sessions in a row of losses. NASDAQ slid 0.81% to $11,360.05, after two consecutive sessions in a row of gains, on what was a somewhat bearish trend trading session today.

Volume

Today’s last reported volume for Pacific Biosciences of California is 6090700 which is 13.11% below its average volume of 7009700.

Pacific Biosciences of California’s last close was $4.24, 88.34% under its 52-week high of $36.36.

Pacific Biosciences of California’s Sales

Pacific Biosciences of California’s sales growth is 17% for the ongoing quarter and 30.3% for the next. The company’s growth estimates for the current quarter and the next is a negative 57.1% and a negative 500%, respectively.

Pacific Biosciences of California’s Revenue

Year-on-year quarterly revenue growth grew by 32.7%, now sitting on 130.51M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Pacific Biosciences of California’s stock is considered to be overbought (>=80).

Pacific Biosciences of California’s Stock Yearly Top and Bottom Value

Pacific Biosciences of California’s stock is valued at $3.93 at 17:32 EST, way under its 52-week high of $36.36 and higher than its 52-week low of $3.85.

Pacific Biosciences of California’s Moving Average

Pacific Biosciences of California’s worth is way under its 50-day moving average of $5.72 and way under its 200-day moving average of $15.27.

More news about Pacific Biosciences of California.

6. ImmunoGen (IMGN) – -6.97%

ImmunoGen, Inc., is a biotechnology company in clinical stage. It develops ADC therapies for cancer. Mirvetuximab Soravtansine is an ADC which targets folate receptor alpha and is currently in Phase III clinical trials for treatment of platinum resistant ovarian carcinoma. IMGN632 is a CD123-targeting ADC in Phase I clinical trials for AML and blastic plasmacytoid cell neplasm. Preclinical programs include IMGC936, an ADC that is being developed in collaboration with MacroGenics, Inc. ImmunoGen, Inc. collaborates with Roche, Amgen/Oxford BioTherapeutics, Bayer HealthCare AG, Eli Lilly and Company, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Fusion Pharmaceuticals Inc., Debiopharm International SA, Jazz Pharmaceuticals Ireland Limited, and MacroGenics, Inc.

NASDAQ ended the session with ImmunoGen sliding 6.97% to $5.01 on Monday while NASDAQ dropped 0.81% to $11,360.05.

Volume

Today’s last reported volume for ImmunoGen is 2196720 which is 41.56% below its average volume of 3759160.

ImmunoGen’s last close was $5.38, 30.76% below its 52-week high of $7.77.

ImmunoGen’s Sales

ImmunoGen’s sales growth is a negative 4.5% for the current quarter and 39.7% for the next. The company’s growth estimates for the current quarter and the next is a negative 46.7% and a negative 38.9%, respectively.

ImmunoGen’s Revenue

Year-on-year quarterly revenue growth declined by 67.4%, now sitting on 69.86M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

ImmunoGen’s stock is considered to be oversold (<=20).

ImmunoGen’s Stock Yearly Top and Bottom Value

ImmunoGen’s stock is valued at $5.01 at 17:32 EST, way below its 52-week high of $7.77 and way higher than its 52-week low of $3.10.

ImmunoGen’s Moving Average

ImmunoGen’s value is way above its 50-day moving average of $4.10 and under its 200-day moving average of $5.38.

More news about ImmunoGen.

7. Celsius Holdings (CELH) – -6.88%

Celsius Holdings, Inc. markets, distributes, sells and promotes functional, calorie-burning, fitness drinks in the United States as well as internationally. It offers a variety of beverages, such as carbonated orange and wild berry, cola and grape, kiwi guava and watermelon. Celsius Heat is a nutritional supplement that contains carbonated flavorings such as orange jack’d and blueberry pomegranate. Blueberry pomegranate. strawberry dragonfruit. tangerine grapefruit. It distributes products via direct-store distribution distributors as well as retailers that include supermarkets and convenience stores as well as drug and nutritional stores and mass merchants. In January 2007, Celsius Holdings, Inc. was established. Celsius Holdings, Inc., was established in 2004. It is located in Boca Raton, Florida.

NASDAQ ended the session with Celsius Holdings falling 6.88% to $75.31 on Monday, after four sequential sessions in a row of gains. NASDAQ dropped 0.81% to $11,360.05, after two successive sessions in a row of gains, on what was a somewhat negative trend trading session today.

Volume

Today’s last reported volume for Celsius Holdings is 1244340 which is 15.56% above its average volume of 1076710.

Celsius Holdings’s last close was $80.87, 26.63% below its 52-week high of $110.22.

Celsius Holdings’s Sales

Celsius Holdings’s sales growth is 117.7% for the present quarter and 64.5% for the next. The company’s growth estimates for the present quarter and the next is 20% and 233.3%, respectively.

Celsius Holdings’s Revenue

Year-on-year quarterly revenue growth grew by 192.3%, now sitting on 314.27M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Celsius Holdings’s stock is considered to be oversold (<=20).

Celsius Holdings’s Stock Yearly Top and Bottom Value

Celsius Holdings’s stock is valued at $75.31 at 17:32 EST, way under its 52-week high of $110.22 and way higher than its 52-week low of $38.31.

Celsius Holdings’s Moving Average

Celsius Holdings’s value is way above its 50-day moving average of $60.70 and way higher than its 200-day moving average of $66.32.

More news about Celsius Holdings.

8. Nano Dimension (NNDM) – -6.74%

NASDAQ ended the session with Nano Dimension falling 6.74% to $3.12 on Monday while NASDAQ dropped 0.81% to $11,360.05.

Volume

Today’s last reported volume for Nano Dimension is 4909120 which is 43.01% above its average volume of 3432630.

Nano Dimension’s last close was $3.34, 64.09% under its 52-week high of $9.30.

Nano Dimension’s Revenue

Year-on-year quarterly revenue growth grew by 282.1%, now sitting on 10.49M for the twelve trailing months.

Nano Dimension’s Stock Yearly Top and Bottom Value

Nano Dimension’s stock is valued at $3.12 at 17:32 EST, way under its 52-week high of $9.30 and way higher than its 52-week low of $2.17.

Nano Dimension’s Moving Average

Nano Dimension’s worth is above its 50-day moving average of $2.90 and way below its 200-day moving average of $4.07.

More news about Nano Dimension.

9. Hycroft Mining Holding Corporation (HYMCZ) – -6.68%

NASDAQ ended the session with Hycroft Mining Holding Corporation falling 6.68% to $0.07 on Monday while NASDAQ slid 0.81% to $11,360.05.

Hycroft Mining Holding Corporation’s last close was $0.06, 26.92% under its 52-week high of $0.08.

Hycroft Mining Holding Corporation’s Stock Yearly Top and Bottom Value

Hycroft Mining Holding Corporation’s stock is valued at $0.07 at 17:32 EST, way below its 52-week high of $0.08 and higher than its 52-week low of $0.07.

More news about Hycroft Mining Holding Corporation.

10. Arcturus Therapeutics (ARCT) – -6.06%

Arcturus Therapeutics Holdings Inc. is an RNA medicine company that focuses on treating respiratory and liver diseases. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. LUNAR, a preclinical drug development program for ornithine transcarbamylase deficiency (OTC), is currently developing mRNA molecules to treat the condition. LUNARCF is developing mRNA compound to replace cystic fibrosis’ transmembrane conductance regulate (CFTR). LUNAR CV and LUNAR MD are internal research programs that target the validation of several pipeline LUNAR mRNA program candidate candidates. LUNAR, nucleic acid and related technologies are owned by the company. Patent applications and portfolios of patents have been filed in 182 countries, including China, Japan, Europe and Japan. To develop rare diseases, it has formed partnerships with Ultragenyx Pharmaceutical, Inc.; Millennium Pharmaceuticals, Inc., Takeda to create a nucleic-acid-based therapeutic candidate; Janssen Pharmaceuticals, Inc., to develop nucleic-acid-based therapeutic candidates to treat hepatitis B; CureVac AG, Singapore Economic Development Board, and Duke-NUS Medical School in order to develop LUNAR-COV19, an anti-Coronavirus vaccine; Catalent, Inc. Arcturus Therapeutics Holdings Inc. is located in San Diego, California.

NASDAQ ended the session with Arcturus Therapeutics dropping 6.06% to $15.73 on Monday, after three consecutive sessions in a row of losses. NASDAQ slid 0.81% to $11,360.05, after two sequential sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Volume

Today’s last reported volume for Arcturus Therapeutics is 258327 which is 66.48% below its average volume of 770878.

Arcturus Therapeutics’s last close was $16.75, 74.23% under its 52-week high of $65.00.

Arcturus Therapeutics’s Sales

Arcturus Therapeutics’s sales growth is 51.9% for the current quarter and a decline by 42.1% for the next. The company’s growth estimates for the current quarter and the next is 15.5% and 22.4%, respectively.

Arcturus Therapeutics’s Revenue

Year-on-year quarterly revenue growth grew by 158.9%, now sitting on 12.36M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Arcturus Therapeutics’s stock is considered to be overbought (>=80).

Arcturus Therapeutics’s Stock Yearly Top and Bottom Value

Arcturus Therapeutics’s stock is valued at $15.73 at 17:33 EST, way below its 52-week high of $65.00 and way above its 52-week low of $11.70.

Arcturus Therapeutics’s Moving Average

Arcturus Therapeutics’s value is below its 50-day moving average of $17.06 and way below its 200-day moving average of $28.41.

More news about Arcturus Therapeutics.

Stay up to date with our winners and losers daily report

LEAVE A REPLY

Please enter your comment!
Please enter your name here